Download Free Conjugates And Malignant Disease Book in PDF and EPUB Free Download. You can read online Conjugates And Malignant Disease and write the review.

This book provides a comprehensive overview of antibody conjugates for in vivo applications. It discusses each of the major classes of antibody conjugates used in cancer diagnosis and therapy, as well as the major chemical and biological aspects of antibody selection, conjugate preparation, characterization, and application. The book is designed to close the information gap that exists regarding these compounds between such diverse disciplines as radiochemists, immunochemists, oncologists, clinicians and immunologists. It also provides a thorough overview for newcomers to the field.
Aiding researchers seeking to eliminate multi-step procedures, reduce delays in treatment and ease patient care, Cancer Theranostics reviews, assesses, and makes pertinent clinical recommendations on the integration of comprehensive in vitro diagnostics, in vivo molecular imaging, and individualized treatments towards the personalization of cancer treatment. Cancer Theranostics describes the identification of novel biomarkers to advance molecular diagnostics of cancer. The book encompasses new molecular imaging probes and techniques for early detection of cancer, and describes molecular imaging-guided cancer therapy. Discussion also includes nanoplatforms incorporating both cancer imaging and therapeutic components, as well as clinical translation and future perspectives. - Supports elimination of multi-step approaches and reduces delays in treatments through combinatorial diagnosis and therapy - Fully assesses cancer theranostics across the emergent field, with discussion of biomarkers, molecular imaging, imaging guided therapy, nanotechnology, and personalized medicine - Content bridges laboratory, clinic, and biotechnology industries to advance biomedical science and improve patient management
Multifunctional Theranostic Nanomedicines in Cancer focuses on new trends, applications, and the significance of novel multifunctional nanotheranostics in cancer imaging for diagnosis and treatment. Cancer nanotechnology offers new opportunities for cancer diagnosis and treatment. Multifunctional nanoparticles harboring various functions—including targeting, imaging, and therapy—have been intensively studied with the goal of overcoming the limitations of conventional cancer diagnosis and therapy. Thus theranostic nanomedicines have emerged in recent years to provide an efficient and safer alternative in cancer management. This book covers polymer-based therapies, lipid-based therapies, inorganic particle-based therapies, photo-related therapies, radiotherapies, chemotherapies, and surgeries. Multifunctional Theranostic Nanomedicines in Cancer offers an indispensable guide for researchers in academia, industry, and clinical settings; it is also ideal for postgraduate students; and formulation scientists working on cancer. - Provides a comprehensive resource of recent scientific progress and novel applications of theranostic nanomedicines - Discusses treatment options from a pharmaceutical sciences perspective - Includes translational science and targeted CNS cancer treatment
This report considers the biological and behavioral mechanisms that may underlie the pathogenicity of tobacco smoke. Many Surgeon General's reports have considered research findings on mechanisms in assessing the biological plausibility of associations observed in epidemiologic studies. Mechanisms of disease are important because they may provide plausibility, which is one of the guideline criteria for assessing evidence on causation. This report specifically reviews the evidence on the potential mechanisms by which smoking causes diseases and considers whether a mechanism is likely to be operative in the production of human disease by tobacco smoke. This evidence is relevant to understanding how smoking causes disease, to identifying those who may be particularly susceptible, and to assessing the potential risks of tobacco products.
Antibody-drug conjugates (ADCs) stand at the verge of a transformation. Scores of clinical programs have yielded only a few regulatory approvals, but a wave of technological innovation now empowers us to overcome past technical challenges. This volume focuses on the next generation of ADCs and the innovations that will enable them. The book inspires the future by integrating the field’s history with novel strategies and cutting-edge technologies. While the book primarily addresses ADCs for solid tumors, the last chapter explores the emerging interest in using ADCs to treat other diseases. The therapeutic rationale of ADCs is strong: to direct small molecules to the desired site of action (and away from normal tissues) by conjugation to antibodies or other targeting moieties. However, the combination of small and large molecules imposes deep complexity to lead optimization, pharmacokinetics, toxicology, analytics and manufacturing. The field has made significant advances in all of these areas by improving target selection, ADC design, manufacturing methods and clinical strategies. These innovations will inspire and educate scientists who are designing next-generation ADCs with the potential to transform the lives of patients.
Cell Press Reviews: Cancer Therapeutics informs, inspires, and connects cancer researchers at all stages in their careers with timely, comprehensive reviews written by leaders in the field and curated by Cell Press editors. The publicatio offers a broad view of some of the most compelling topics in cancer therapeutics including: - Genetic approaches for personal oncology - Targeting epigenetic dysregulation and protein interaction networks - Vaccines and antibodies in cancer immunotherapy - Tumor heterogeneity and chemotherapy resistance - Tumor associated macrophages in anticancer treatment Contributions come from leading voices in the field, including: - Daniel A. Haber, Director of Massachusetts General Hospital Cancer Center and Professor at Harvard Medical School - Tony Kouzarides, Professor at the University of Cambridge, Deputy Director of the Wellcome Trust/Cancer Research UK Gurdon Institute, and a founder of the cancer drug discovery company Chroma Therapeutics - Charles L. Sawyers, Chair of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center, President of the American Association for Cancer Research, member of the presidentially appointed National Cancer Advisory Board, and recipient of the 2013 Breakthrough Prize in Life Sciences Cell Press Reviews: Cancer Therapeutics is part of the Cell Press Reviews series, which features reviews published in Cell Press primary research and Trends reviews journals. - Provides timely, comprehensive articles on a wide range of topics in cancer therapeutics - Offers insight from experts on genetic, molecular, and cellular aspects of cancer therapy - Features reviews on basic science advances translated into drug discovery and therapeutic approaches - Includes articles originally published in Cell, Cancer Cell, Trends in Genetics, Trends in Molecular Medicine, and Trends in Pharmacological Sciences
Over the past 5 years, clinical immunology, as a whole, has advanced more rapidly than over the past 20 years. Many of these advances have been que to monoclonal antibody technology with its ability to identify antigens on tumour cells with a precision never before available. Monoclonal antibodies have the ability to identify subsets of human T-Iymphocytes and aid in diagnosis of both immunodeficiency disorders such as AIDS, or autoimmune diseases, and they can be adapted as drug targeting agents. Additionally, however, major advances have been made in identifying immunomodulating agents, and the last year has seen two such agents, IL-2 and OKT3, made available commercially for such intervention. Furthermore, another immuno modulating technique, bone marrow transplantation, ha~ now been established as a curative modality in leukaemia treatment. A central issue in tumour immunology is whether human tumours express antigens which can be termed tumour-specific. This has important implications for both tumour immunity as well as drug targeting. This issue is considered in detail by R. A. Robins in the introductory chapter in which the expression of antigens in human tumours is compared with that in experimentally induced animal tumours. This controversial issue is also considered in later chapters by Bast in breast carcinoma, Riimke and de Vries in melanoma, V{mky in lung cancer, Armitage in colorectal cancer, and Paulie and Perlmann in bladder carcinoma.
Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates today's available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists. - Covers the diagnosis, treatments and targeted therapies, and management of breast cancers that are HER2-positive. - Contains sections on background and testing, advanced disease, therapeutics, and toxicity considerations. - Includes a timely section on innovative future therapies.
Antibody-drug conjugates (ADCs) represent a promising therapeutic approach for cancer patients by combining the antigen-targeting specificity of monoclonal antibodies (mAbs) with the cytotoxic potency of chemotherapeutic drugs. In Antibody-Drug Conjugates, expert researchers provide detailed protocols for many of the key ADC techniques necessary for working in the field. These chapters and methodologies are aimed at the key tasks necessary to identify a suitable target, properly design the mAb, the linker and the payload, as well as to conjugate them in a reproducible and scalable fashion. Written in the highly successful Methods in Molecular BiologyTM format, these detailed chapters include the kind of practical implementation advice that guarantees quality results. Authoritative and timely, Antibody-Drug Conjugates aims to further drive ADC development and thus help toward improving cancer treatments of the future.
In this book, leading experts in cancer immunotherapy join forces to provide a comprehensive guide that sets out the main principles of oncoimmunology and examines the latest advances and their implications for clinical practice, focusing in particular on drugs with FDA/EMA approvals and breakthrough status. The aim is to deliver a landmark educational tool that will serve as the definitive reference for MD and PhD students while also meeting the needs of established researchers and healthcare professionals. Immunotherapy-based approaches are now inducing long-lasting clinical responses across multiple histological types of neoplasia, in previously difficult-to-treat metastatic cancers. The future challenges for oncologists are to understand and exploit the cellular and molecular components of complex immune networks, to optimize combinatorial regimens, to avoid immune-related side effects, and to plan immunomonitoring studies for biomarker discovery. The editors hope that this book will guide future and established health professionals toward the effective application of cancer immunology and immunotherapy and contribute significantly to further progress in the field.